376 related articles for article (PubMed ID: 21532503)
21. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
[TBL] [Abstract][Full Text] [Related]
22. nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer.
Hirsh V
Expert Rev Anticancer Ther; 2014 Feb; 14(2):129-41. PubMed ID: 24467217
[TBL] [Abstract][Full Text] [Related]
23. Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence.
Adrianzen Herrera D; Ashai N; Perez-Soler R; Cheng H
Expert Opin Pharmacother; 2019 Jan; 20(1):95-102. PubMed ID: 30439289
[TBL] [Abstract][Full Text] [Related]
24. Initial testing (stage 1) of the tubulin binding agent nanoparticle albumin-bound (nab) paclitaxel (Abraxane(®)) by the Pediatric Preclinical Testing Program (PPTP).
Houghton PJ; Kurmasheva RT; Kolb EA; Gorlick R; Maris JM; Wu J; Tong Z; Arnold MA; Chatterjee M; Williams TM; Smith MA
Pediatr Blood Cancer; 2015 Jul; 62(7):1214-21. PubMed ID: 25809532
[TBL] [Abstract][Full Text] [Related]
25. Antitumor efficacy of solid dispersion of paclitaxel prepared by supercritical antisolvent process in human mammary tumor xenografts.
Shanmugam S; Park JH; Chi SC; Yong CS; Choi HG; Woo JS
Int J Pharm; 2011 Jan; 403(1-2):130-5. PubMed ID: 20974239
[TBL] [Abstract][Full Text] [Related]
26. SPARC is expressed in human uveal melanoma and its abrogation reduces tumor cell proliferation.
Maloney SC; Marshall JC; Antecka E; Orellana ME; Fernandes BF; Martins C; Castiglione E; DI Cesare S; Logan P; Burnier MN
Anticancer Res; 2009 Aug; 29(8):3059-64. PubMed ID: 19661316
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
28. Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma.
Wagner LM; Yin H; Eaves D; Currier M; Cripe TP
Pediatr Blood Cancer; 2014 Nov; 61(11):2096-8. PubMed ID: 24753077
[TBL] [Abstract][Full Text] [Related]
29. LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
Yang C; Wang H; Zhang B; Chen Y; Zhang Y; Sun X; Xiao G; Nan K; Ren H; Qin S
J Exp Clin Cancer Res; 2016 Sep; 35(1):158. PubMed ID: 27737687
[TBL] [Abstract][Full Text] [Related]
30. Aberrant methylation of SPARC in human lung cancers.
Suzuki M; Hao C; Takahashi T; Shigematsu H; Shivapurkar N; Sathyanarayana UG; Iizasa T; Fujisawa T; Hiroshima K; Gazdar AF
Br J Cancer; 2005 Mar; 92(5):942-8. PubMed ID: 15756262
[TBL] [Abstract][Full Text] [Related]
31. First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel.
Gupta N; Hatoum H; Dy GK
Int J Nanomedicine; 2014; 9():209-21. PubMed ID: 24399877
[TBL] [Abstract][Full Text] [Related]
32. Mixed micelles of PEG(2000)-DSPE and vitamin-E TPGS for concurrent delivery of paclitaxel and parthenolide: enhanced chemosenstization and antitumor efficacy against non-small cell lung cancer (NSCLC) cell lines.
Gill KK; Kaddoumi A; Nazzal S
Eur J Pharm Sci; 2012 May; 46(1-2):64-71. PubMed ID: 22369858
[TBL] [Abstract][Full Text] [Related]
33. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting.
Lu H; Li B; Kang Y; Jiang W; Huang Q; Chen Q; Li L; Xu C
Cancer Chemother Pharmacol; 2007 Feb; 59(2):175-81. PubMed ID: 16718469
[TBL] [Abstract][Full Text] [Related]
34. In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.
Fahham D; Weiss ID; Abraham M; Beider K; Hanna W; Shlomai Z; Eizenberg O; Zamir G; Izhar U; Shapira OM; Peled A; Wald O
J Thorac Cardiovasc Surg; 2012 Nov; 144(5):1167-1175.e1. PubMed ID: 22925564
[TBL] [Abstract][Full Text] [Related]
35. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
36. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer.
Green MR; Manikhas GM; Orlov S; Afanasyev B; Makhson AM; Bhar P; Hawkins MJ
Ann Oncol; 2006 Aug; 17(8):1263-8. PubMed ID: 16740598
[TBL] [Abstract][Full Text] [Related]
37. Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma.
Pascual-Pasto G; Resa-Pares C; Castillo-Ecija H; Aschero R; Baulenas-Farres M; Vila-Ubach M; Burgueño V; Balaguer-Lluna L; Cuadrado-Vilanova M; Olaciregui NG; Martinez-Velasco N; Perez-Jaume S; de Alava E; Tirado OM; Lavarino C; Mora J; Carcaboso AM
Biochem Pharmacol; 2023 Feb; 208():115408. PubMed ID: 36603685
[TBL] [Abstract][Full Text] [Related]
38. Taxanes, past, present, and future impact on non-small cell lung cancer.
Joshi M; Liu X; Belani CP
Anticancer Drugs; 2014 May; 25(5):571-83. PubMed ID: 24463482
[TBL] [Abstract][Full Text] [Related]
39. Investigating the relationship between secreted protein acidic and rich in cysteine expression level and therapeutic efficacy of nab-paclitaxel: a meta-analysis.
Zhou X; Zhang L; Qierang C; Huang M; Yang X; Li L; Jiang J
Transl Cancer Res; 2021 Feb; 10(2):876-885. PubMed ID: 35116417
[TBL] [Abstract][Full Text] [Related]
40. Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors.
Zhang L; Marrano P; Kumar S; Leadley M; Elias E; Thorner P; Baruchel S
Clin Cancer Res; 2013 Nov; 19(21):5972-83. PubMed ID: 23989978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]